Search SAMHSA Publications and Digital Products
Store Facets Summary
Main page content
Published: December 2021This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.
Published: August 2021The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
Published: July 2021This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
Routine Administration of Cognitive Behavioral Therapy for Psychosis as the Standard of Care for Individuals Seeking Treatment for Psychosis
Published: May 2021This guide provides mental health decision-makers (e.g., state/local mental health directors, treatment facility clinical directors, and other stakeholders) with rationale and evidence to support wide-spread expansion of Cognitive Behavioral Therapy for Psychosis (CBTp) across mental health systems.
Published: January 2021This Advisory is based on TIP 27, Comprehensive Case Management for Substance Abuse Treatment. It surveys the underlying principles and models of case management, discusses reasons substance use disorder (SUD) treatment providers might consider implementing or expanding the use of case management, and lists some case management-related resources and tools.
Published: January 2021This Advisory is based on TIP 35, Enhancing Motivation for Change in Substance Use Disorder Treatment. It addresses the spirit, application, and fundamentals of motivational interviewing (MI), discusses how practitioners can effectively employ MI in substance use disorder (SUD) treatment, and provides tools that practitioners can use to encourage and promote lasting positive outcomes for their clients.
Published: January 2021This Advisory, based on TIP 49, Incorporating Alcohol Pharmacotherapies Into Medical Practice, focuses on medication and related treatment decisions made after screening and assessment for AUD, and medically supervised withdrawal, if necessary. Alcohol consumption should not stop abruptly in those patients who have consumed alcohol regularly over a prolonged period of time. This Advisory is meant as an overview of AUD medications to facilitate abstinence.